Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | How It Works Previous | All Articles This Week | Next
This article originally posted 19 July, 2011 and appeared in  MedicationGLP-1 Series Issue 7GLP-1 Series Issue 8GLP-1 Receptor Agonist Therapy

GLP-1 Knowledge Survey Part V

Over the past few weeks we have been looking at your colleagues' responses to questions about GLP-1, including mechanisms, interactions, dosing and effectiveness. Over the next two weeks we will examine some of your opinions on starting doses and selecting patients....

Advertisement

We decided to start by looking at your prescribing habits and who would be best to start on GLP-1 therapy.

AACE has indicated in their guidelines that the use of a GLP-1 Analog is indicated first line and when we put the question to our readers, those who had an opinion felt that they were unlikely to recommend GLP-1s as monotherapy. We noted with interest that the prescribers, NP's and Physicians, were the least likely to recommend first line. In comparison, when we looked at the use of GLP-1 analogs as add on therapy, the NP's and Physicians were anxious to prescribe, with 80% of physicians and 75% of NP's likely to use these important medications.

 
GLP1-7-Ch1
 
GLP1-7-Ch2
 
Most of our respondents felt that they would be likely to use GLP-1 Analog therapy if it meant that patients might be able to reduce the complexity of their medication and NP's were 100% in agreement that using a GLP-1 Analog in complex regimens was a great idea. This is especially interesting when you consider that the idea of using an injectable is important to a majority of the respondents.
 
GLP-1-7-Ch3
 
GLP1-7-Ch4
Although the risk of hypoglycemia is very low due to the glucose regulating effect of GLP-1 analogs, I was especially surprised by the large number of all respondents who would avoid using GLP-1 therapy because of the perceived risk of hypoglycemia.
 
GLP1-7-Ch5
All agreed that if a patient is motivated, they would be more likely to use GLP-1 therapy but most respondents did not accurately describe the benefits even though they were familiar with them.
 
GLP1-7-Ch6

 

Click below to access other articles in this series:

GLP-1 Knowledge Survey Part I

GLP-1 Knowledge Survey Part II

GLP-1 Knowledge Survey Part III

GLP-1 Knowledge Survey Part IV

GLP-1 Knowledge Survey Part V

GLP-1 Knowledge Survey, Part VI

Copyright © 2011 Diabetes In Control, Inc.

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 19 July, 2011 and appeared in  MedicationGLP-1 Series Issue 7GLP-1 Series Issue 8GLP-1 Receptor Agonist Therapy

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control
Search Articles On Diabetes In Control